Lupin
Lupin Limited, commonly referred to as Lupin, is a prominent global player in the pharmaceutical industry, headquartered in Mumbai, India. Founded in 1968, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Lupin is renowned for its diverse portfolio, which encompasses generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With a commitment to innovation, Lupin has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is particularly noted for its leadership in the anti-TB and cardiovascular segments, offering unique products that cater to unmet medical needs. As a result, Lupin has secured a competitive market position, consistently ranking among the top generic pharmaceutical companies globally.
DitchCarbon Score
How does Lupin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin's score of 55 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lupin's reported carbon emissions
In 2023, Lupin reported total carbon emissions of approximately 410,755,000 kg CO2e. This figure includes Scope 1 emissions of about 86,910,000 kg CO2e, Scope 2 emissions of around 323,845,000 kg CO2e, and significant Scope 3 emissions totalling approximately 854,936,000 kg CO2e. Over the years, Lupin's emissions have shown fluctuations, with total emissions recorded at about 446,292,000 kg CO2e in 2022 and 487,676,000 kg CO2e in 2021. The company has committed to near-term emissions reduction targets, although specific numerical targets have not been disclosed. Notably, Lupin has not yet committed to a net-zero target. Lupin is actively engaged in climate initiatives, having signed the Amazon Climate Pledge in November 2024, which underscores its commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company continues to monitor and report its emissions across all three scopes, demonstrating a commitment to transparency and accountability in its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 103,887,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 371,883,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 680,968,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lupin is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
